Molecular Diagnostics
Genomic and molecular diagnostic testing companies.
Leadership as of 2026-10-27: Weakening. Relative to SPY: 5 sessions +9.9pp, 21 sessions +15.9pp, 63 sessions +56.9pp. Participation 80%; 5 of 5 members eligible.
- 63-session excess +38.2pp (robust) still positive
- 21-session excess fell -4.4pp in 5 sessions
Economic family: Biotechnology
Member companies
Related themes
- Large-Cap Biopharma: Leading — 21-session vs SPY +6.1pp, participation 75%
- Neuro / CNS: Neutral — 21-session vs SPY −0.2pp, participation 43%
- Immunology & Inflammation: Lagging — 21-session vs SPY −3.6pp, participation 29%
- Rare & Genetic Disease: Lagging — 21-session vs SPY −3.6pp, participation 32%
- RNA Therapeutics: Lagging — 21-session vs SPY −4.2pp, participation 40%
- Oncology: Lagging — 21-session vs SPY −8.2pp, participation 32%
- Gene Therapy: Lagging — 21-session vs SPY −16.6pp, participation 0%
- Targeted Protein Degradation: Tracked (too few stocks for a leadership state) — 21-session vs SPY +2.4pp, participation 67%